Hydrogel could starve tumors by cutting off their blood supply
NCT ID NCT04523350
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests a new liquid gel called Instylla HES that is injected into blood vessels feeding hypervascular tumors (tumors with many blood vessels). The gel hardens to block blood flow, starving the tumor. Researchers compare it to standard embolization treatments in about 150 adults with liver, kidney, or other hypervascular tumors. The goal is to see if the gel works as well as standard care and has an acceptable safety profile.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Instylla Hydrogel Embolic System (a liquid gel that blocks blood vessels)
What this could lead to
If successful, this hydrogel could offer a simpler, more consistent way to cut off blood supply to tumors, potentially improving outcomes for people with liver, kidney, or other hypervascular cancers.
What could go wrong
This is a mid-stage trial with 150 participants, so results may not apply to everyone. The hydrogel is new, and there is a risk of serious side effects like unintended blockage or damage to nearby tissues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERVASCULAR TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Central Arkansas Radiation Therapy Institute, Inc.
Little Rock, Arkansas, 72205, United States
-
Charlotte Radiology
Charlotte, North Carolina, 28202, United States
-
Memorial Health Services
Long Beach, California, 92708, United States
-
Mount Sinai
Toronto, Ontario, M5G 1Z5, Canada
-
New York and Presbyterian Hospital (Cornell/Weill Medical College)
New York, New York, 10065, United States
-
Olive View-UCLA Education & Research Institute
Sylmar, California, 91342-1495, United States
-
St. Elizabeth Healthcare
Edgewood, Kentucky, 41017, United States
-
Summit Health
Florham Park, New Jersey, 07932, United States
-
Sunnybrook Research Institute
Toronto, Ontario, M4N 3M5, Canada
-
Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
-
UAB Hospital
Birmingham, Alabama, 35233, United States
-
University of California, Irvine
Irvine, California, 92697- 7600, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104-6061, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States